Tertiary lymphoid structures may help predict breast cancer outcomes but need clearer definitions

Breast cancer patients often carry tertiary lymphoid structures, which are clusters of immune cells that form inside tumors. These clusters suggest the body is trying to fight the cancer, but their presence does not always mean a better outcome. A recent review looked at how these structures relate to disease progression and survival in breast cancer patients. The authors found that the biological and clinical significance of these structures is highly heterogeneous. This means the impact varies greatly from person to person and cannot be captured by a simple positive versus negative classification. Without standardized classification, it is hard to compare results across different studies or apply findings to real patients. The review highlights that while these structures represent a promising biomarker, their use depends heavily on context. More research is needed to understand the mechanisms behind them before they can guide treatment decisions confidently.